5377 Results

People

  1. O'Reilly
    O'Reilly
  2. Usmani
    Usmani
  3. Abu-Rustum
    Abu-Rustum
  4. Dee
    Dee
  5. Wei
    Wei
  6. Kingham
    Kingham
  7. Jarnagin
    Jarnagin
  8. Lee
    Lee
  9. Weigelt
    Weigelt
  10. Drilon
    Drilon

Groups

  1. Department of Medicine (2141)
  2. Solid Tumor Oncology Division (1382)
  3. Sloan Kettering Institute Postdocs (1038)
  4. Surgery (984)
  5. Graduate Medical Education (883)
  6. GSK Faculty (868)
  7. Survivorship Research (802)
  8. Population Sciences Research Program (722)
  9. Department of Pathology and Laboratory Medicine (719)
  10. Hematologic Malignancies, Division of (670)
  1. "2024"
Formats
  1. Journal Article (2329)
  2. Meeting Abstract (1694)
  3. Review (589)
  4. Editorial (305)
  5. Book Section (98)
  6. Correspondence (92)
  7. Guidelines (90)
  8. Research Letter (89)
  9. Miscellaneous (55)
  10. Conference Paper (33)
  11. Book Whole (3)
Groups
  1. Department of Medicine (2141)
  2. Solid Tumor Oncology Division (1382)
  3. Sloan Kettering Institute Postdocs (1038)
  4. Surgery (984)
  5. Graduate Medical Education (883)
  6. GSK Faculty (868)

More Groups

People
  1. Eileen O'Reilly (75)
  2. Saad Usmani (75)
  3. Edward Christopher Dee (70)
  4. Nadeem Abu-Rustum (70)
  5. Alice Wei (69)
  6. T Peter Kingham (68)

More People

Years
  1. 2024 (5377)
Publications
  1. Journal of Clinical Oncology (521)
  2. International Journal of Radiation Oncology, Biology, Physics (186)
  3. Blood (161)
  4. Annals of Oncology (147)
  5. Annals of Surgical Oncology (131)
  6. Laboratory Investigation (91)

More Publications

Publishers
  1. Elsevier Inc. (784)
  2. American Society of Clinical Oncology (580)
  3. Nature Publishing Group (384)
  4. Springer (357)
  5. Oxford University Press (347)
  6. Elsevier Science, Inc. (256)

More Publishers

Results (5377)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)
    Meeting Abstract

    Janjigian, Y. Y.; van Laarhoven, H. W. M.; Rha, S. Y.; Kozlov, V.; Oh, D. Y.; Gravina, A.; Rapatoni, L.; Shoji, H.; Hofheinz, R. D.; Chen, L. T.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase III study of pembrolizumab plus MK-1084 vs pembrolizumab plus placebo as first-line treatment for metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation and PD-L1 tumour proportion score (TPS) ≥50%: MK-1084-004
    Meeting Abstract

    Cobb, P. W.; Hochmair, M.; Schuler, M. H. H.; Riely, G. J.; Rojas, C. I.; Kim, S. J.; Chen, X.; Lara-Guerra, H.; Felip, E.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Zanidatamab + chemotherapy for first-line (1L) treatment of HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma (mGEA): New and updated data from a phase II trial
    Meeting Abstract

    Elimova, E.; Ajani, J. A.; Burris, H. A.; Denlinger, C. S.; Iqbal, S.; Kang, Y. K.; Kim, J. H.; Lee, K. W.; Lin, B.; Mehta, R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J. P.; Yanez Weber, P. E.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • TRIDENT: Machine learning (ML) multimodal signatures to identify patients that would benefit most from tremelimumab (T) addition to durvalumab (D) + chemotherapy (CT) with data from the POSEIDON trial
    Meeting Abstract

    Skoulidis, F.; Jabbour, S.; Garon, E. B.; Iyengar, P.; Scagliotti, G.; Ferrer, L.; Etchepare, G.; Gallinato, O.; Faure, J.; Bernard, P.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Sotorasib long-term clinical outcomes in pretreated KRAS G12C-mutated advanced NSCLC: Pooled analysis from the CodeBreaK clinical trials
    Meeting Abstract

    Skoulidis, F.; Li, B. T.; Hochmair, M. J.; Govindan, R.; Vincent, M.; Van Der Wekken, A. J.; Reguart Aransay, N.; O'Byrne, K. J.; Girard, N.; Griesinger, F.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A population-level prognostic score model for early acquired resistance to frontline anti-PD-(L)1 therapy in metastatic non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Murray, J. C.; Huang, Q.; Hu, C.; Curran, E.; Wong, C.; Glatz, L.; Wang, T.; Hasan, A.; Villaruz, L.; Schoenfeld, A.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer
    Meeting Abstract

    Di Federico, A.; Chen, M. F.; Pagliaro, A.; Ogliari, F. R.; Stockhammer, P.; Aldea, M.; Grant, M.; De Giglio, A.; Alessi, J. V.; Pecci, F.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • METxMET bispecific antibody davutamig (REGN5093) for MET-altered advanced non-small cell lung cancer (aNSCLC): Update from a first-in-human (FIH) study
    Meeting Abstract

    Cho, B. C.; Ahn, M. J.; Kim, T. M.; Kim, S. W.; Han, J. Y.; Kim, C.; Shim, B.; Ricordel, C.; Drilon, A. E.; Pujol, J. L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC
    Meeting Abstract

    Krebs, M. G.; Lu, S.; Fan, Y.; Yu, Y.; Drilon, A. E.; Siena, S.; Xue, C.; Bradley, D.; Hu, X.
    Annals of Oncology (2024)

    Fulltext@MSK | Save